$XLRN Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ACCELERON PHARMA INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in ACCELERON PHARMA INC. Get notifications about new insider transactions in ACCELERON PHARMA INC for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 08 2021 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | SVP, General Counse ... | Payment of Exercise | F | 126.69 | 108 | 13,683 | 20,923 | 21 K to 20.9 K (-0.51 %) |
| Apr 21 2021 | XLRN | ACCELERON PHARMA I ... | MCCOURT Thomas A | Director | Option Exercise | M | 40.61 | 7,500 | 304,575 | 0 | |
| Apr 21 2021 | XLRN | ACCELERON PHARMA I ... | MCCOURT Thomas A | Director | Sell | S | 121.23 | 200 | 24,246 | 6,044 | 6.2 K to 6 K (-3.20 %) |
| Apr 21 2021 | XLRN | ACCELERON PHARMA I ... | MCCOURT Thomas A | Director | Sell | S | 120.16 | 1,143 | 137,343 | 6,244 | 7.4 K to 6.2 K (-15.47 %) |
| Apr 21 2021 | XLRN | ACCELERON PHARMA I ... | MCCOURT Thomas A | Director | Sell | S | 119.36 | 4,030 | 481,021 | 7,387 | 11.4 K to 7.4 K (-35.30 %) |
| Apr 21 2021 | XLRN | ACCELERON PHARMA I ... | MCCOURT Thomas A | Director | Sell | S | 118.39 | 2,127 | 251,816 | 11,417 | 13.5 K to 11.4 K (-15.70 %) |
| Apr 21 2021 | XLRN | ACCELERON PHARMA I ... | MCCOURT Thomas A | Director | Buy | M | 40.61 | 7,500 | 304,575 | 13,544 | 6 K to 13.5 K (+124.09 %) |
| Apr 05 2021 | XLRN | ACCELERON PHARMA I ... | Zakrzewski Joseph S | Director | Option Exercise | M | 24.11 | 10,000 | 241,100 | 0 | |
| Apr 05 2021 | XLRN | ACCELERON PHARMA I ... | Zakrzewski Joseph S | Director | Sell | S | 142.27 | 1,100 | 156,497 | 34,499 | 35.6 K to 34.5 K (-3.09 %) |
| Apr 05 2021 | XLRN | ACCELERON PHARMA I ... | Zakrzewski Joseph S | Director | Sell | S | 141.28 | 2,152 | 304,035 | 35,599 | 37.8 K to 35.6 K (-5.70 %) |
| Apr 05 2021 | XLRN | ACCELERON PHARMA I ... | Zakrzewski Joseph S | Director | Sell | S | 140.31 | 6,748 | 946,812 | 37,751 | 44.5 K to 37.8 K (-15.16 %) |
| Apr 05 2021 | XLRN | ACCELERON PHARMA I ... | Zakrzewski Joseph S | Director | Buy | M | 24.11 | 10,000 | 241,100 | 44,499 | 34.5 K to 44.5 K (+28.99 %) |
| Apr 05 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Option Exercise | M | 52.99 | 2,050 | 108,630 | 4,085 | |
| Apr 05 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Option Exercise | M | 41.64 | 1,875 | 78,075 | 3,750 | |
| Apr 05 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Option Exercise | M | 35.34 | 5,000 | 176,700 | 10,000 | |
| Apr 05 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Sell | S | 141.15 | 641 | 90,477 | 1,622 | 2.3 K to 1.6 K (-28.33 %) |
| Apr 05 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Sell | S | 140.13 | 11,223 | 1,572,679 | 2,263 | 13.5 K to 2.3 K (-83.22 %) |
| Apr 05 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Buy | M | 52.99 | 2,050 | 108,630 | 13,486 | 11.4 K to 13.5 K (+17.93 %) |
| Apr 05 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Buy | M | 41.64 | 1,875 | 78,075 | 11,436 | 9.6 K to 11.4 K (+19.61 %) |
| Apr 05 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Buy | M | 35.34 | 5,000 | 176,700 | 9,561 | 4.6 K to 9.6 K (+109.63 %) |
| Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Zakrzewski Joseph S | Director | Option Exercise | M | 24.11 | 10,000 | 241,100 | 10,000 | |
| Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Zakrzewski Joseph S | Director | Sell | S | 135.67 | 1,600 | 217,072 | 34,499 | 36.1 K to 34.5 K (-4.43 %) |
| Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Zakrzewski Joseph S | Director | Sell | S | 135.22 | 1,700 | 229,874 | 36,099 | 37.8 K to 36.1 K (-4.50 %) |
| Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Zakrzewski Joseph S | Director | Sell | S | 134.27 | 6,596 | 885,645 | 37,799 | 44.4 K to 37.8 K (-14.86 %) |
| Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Zakrzewski Joseph S | Director | Sell | S | 132.61 | 104 | 13,791 | 44,395 | 44.5 K to 44.4 K (-0.23 %) |
| Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Zakrzewski Joseph S | Director | Buy | M | 24.11 | 10,000 | 241,100 | 44,499 | 34.5 K to 44.5 K (+28.99 %) |
| Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Option Exercise | M | 52.99 | 2,050 | 108,630 | 6,135 | |
| Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Option Exercise | M | 41.64 | 1,875 | 78,075 | 5,625 | |
| Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Option Exercise | M | 35.34 | 5,000 | 176,700 | 15,000 | |
| Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Sell | S | 137.92 | 941 | 129,783 | 4,561 | 5.5 K to 4.6 K (-17.10 %) |
| Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Sell | S | 136.92 | 3,796 | 519,748 | 5,502 | 9.3 K to 5.5 K (-40.83 %) |
| Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Sell | S | 136.22 | 2,987 | 406,889 | 9,298 | 12.3 K to 9.3 K (-24.31 %) |
| Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Sell | S | 134.54 | 1,201 | 161,583 | 12,285 | 13.5 K to 12.3 K (-8.91 %) |
| Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Buy | M | 52.99 | 2,050 | 108,630 | 13,486 | 11.4 K to 13.5 K (+17.93 %) |
| Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Buy | M | 41.64 | 1,875 | 78,075 | 11,436 | 9.6 K to 11.4 K (+19.61 %) |
| Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Buy | M | 35.34 | 5,000 | 176,700 | 9,561 | 4.6 K to 9.6 K (+109.63 %) |
| Mar 04 2021 | XLRN | ACCELERON PHARMA I ... | KANGO SUJAY | EVP, Chief Commerci ... | Option Exercise | M | 40.61 | 5,000 | 203,050 | 35,000 | |
| Mar 04 2021 | XLRN | ACCELERON PHARMA I ... | KANGO SUJAY | EVP, Chief Commerci ... | Sell | S | 138.15 | 200 | 27,630 | 19,396 | 19.6 K to 19.4 K (-1.02 %) |
| Mar 04 2021 | XLRN | ACCELERON PHARMA I ... | KANGO SUJAY | EVP, Chief Commerci ... | Sell | S | 137.12 | 600 | 82,272 | 19,596 | 20.2 K to 19.6 K (-2.97 %) |
| Mar 04 2021 | XLRN | ACCELERON PHARMA I ... | KANGO SUJAY | EVP, Chief Commerci ... | Sell | S | 136.24 | 1,501 | 204,496 | 20,196 | 21.7 K to 20.2 K (-6.92 %) |
| Mar 04 2021 | XLRN | ACCELERON PHARMA I ... | KANGO SUJAY | EVP, Chief Commerci ... | Sell | S | 135.48 | 2,699 | 365,661 | 21,697 | 24.4 K to 21.7 K (-11.06 %) |
| Mar 04 2021 | XLRN | ACCELERON PHARMA I ... | KANGO SUJAY | EVP, Chief Commerci ... | Buy | M | 40.61 | 5,000 | 203,050 | 24,396 | 19.4 K to 24.4 K (+25.78 %) |
| Feb 02 2021 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | SVP, General Counse ... | Option Exercise | A | 115.53 | 18,806 | 2,172,657 | 18,806 | |
| Feb 02 2021 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | SVP, General Counse ... | Grant | A | 0.00 | 4,868 | 0 | 21,031 | 16.2 K to 21 K (+30.12 %) |
| Feb 02 2021 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | A | 115.53 | 18,806 | 2,172,657 | 18,806 | |
| Feb 02 2021 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Grant | A | 0.00 | 4,868 | 0 | 10,681 | 5.8 K to 10.7 K (+83.74 %) |
| Feb 02 2021 | XLRN | ACCELERON PHARMA I ... | KANGO SUJAY | EVP, Chief Commerci ... | Option Exercise | A | 115.53 | 20,896 | 2,414,115 | 20,896 | |
| Feb 02 2021 | XLRN | ACCELERON PHARMA I ... | KANGO SUJAY | EVP, Chief Commerci ... | Grant | A | 0.00 | 5,409 | 0 | 19,396 | 14 K to 19.4 K (+38.67 %) |
| Feb 02 2021 | XLRN | ACCELERON PHARMA I ... | Backstrom Jay T. | EVP, Research and D ... | Option Exercise | A | 115.53 | 20,896 | 2,414,115 | 20,896 | |
| Feb 02 2021 | XLRN | ACCELERON PHARMA I ... | Backstrom Jay T. | EVP, Research and D ... | Grant | A | 0.00 | 5,409 | 0 | 20,781 | 15.4 K to 20.8 K (+35.19 %) |
| Feb 02 2021 | XLRN | ACCELERON PHARMA I ... | Dable Habib J | CEO and President | Option Exercise | A | 115.53 | 64,361 | 7,435,626 | 64,361 | |
| Feb 02 2021 | XLRN | ACCELERON PHARMA I ... | Dable Habib J | CEO and President | Grant | A | 0.00 | 16,662 | 0 | 98,450 | 81.8 K to 98.5 K (+20.37 %) |
| Feb 02 2021 | XLRN | ACCELERON PHARMA I ... | Zakrzewski Joseph S | Director | Option Exercise | A | 115.53 | 3,222 | 372,238 | 3,222 | |
| Feb 02 2021 | XLRN | ACCELERON PHARMA I ... | Zakrzewski Joseph S | Director | Grant | A | 0.00 | 1,622 | 0 | 34,499 | 32.9 K to 34.5 K (+4.93 %) |
| Feb 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Option Exercise | A | 115.53 | 3,222 | 372,238 | 3,222 | |
| Feb 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Grant | A | 0.00 | 1,622 | 0 | 4,561 | 2.9 K to 4.6 K (+55.19 %) |
| Feb 02 2021 | XLRN | ACCELERON PHARMA I ... | MCCOURT Thomas A | Director | Option Exercise | A | 115.53 | 3,222 | 372,238 | 3,222 | |
| Feb 02 2021 | XLRN | ACCELERON PHARMA I ... | MCCOURT Thomas A | Director | Grant | A | 0.00 | 1,622 | 0 | 6,044 | 4.4 K to 6 K (+36.68 %) |
| Feb 02 2021 | XLRN | ACCELERON PHARMA I ... | Malik Kemal | Director | Option Exercise | A | 115.53 | 3,222 | 372,238 | 3,222 | |
| Feb 02 2021 | XLRN | ACCELERON PHARMA I ... | Malik Kemal | Director | Grant | A | 0.00 | 1,622 | 0 | 1,622 | 0 to 1.6 K |
| Jan 06 2021 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | SVP, General Counse ... | Sell | S | 124.30 | 100 | 12,430 | 16,163 | 16.3 K to 16.2 K (-0.61 %) |
| Jan 06 2021 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | SVP, General Counse ... | Sell | S | 122.93 | 56 | 6,884 | 16,263 | 16.3 K to 16.3 K (-0.34 %) |
| Jan 06 2021 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | SVP, General Counse ... | Sell | S | 122.46 | 1,900 | 232,674 | 16,319 | 18.2 K to 16.3 K (-10.43 %) |
| Jan 06 2021 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | SVP, General Counse ... | Payment of Exercise | F | 124.31 | 942 | 117,100 | 18,219 | 19.2 K to 18.2 K (-4.92 %) |
| Jan 06 2021 | XLRN | ACCELERON PHARMA I ... | KANGO SUJAY | EVP, Chief Commerci ... | Sell | S | 126.15 | 4,624 | 583,318 | 3,987 | 8.6 K to 4 K (-53.70 %) |
| Jan 06 2021 | XLRN | ACCELERON PHARMA I ... | KANGO SUJAY | EVP, Chief Commerci ... | Sell | S | 125.17 | 3,429 | 429,208 | 8,611 | 12 K to 8.6 K (-28.48 %) |
| Jan 06 2021 | XLRN | ACCELERON PHARMA I ... | KANGO SUJAY | EVP, Chief Commerci ... | Sell | S | 123.90 | 1,947 | 241,233 | 12,040 | 14 K to 12 K (-13.92 %) |
| Jan 06 2021 | XLRN | ACCELERON PHARMA I ... | KANGO SUJAY | EVP, Chief Commerci ... | Payment of Exercise | F | 124.31 | 1,357 | 168,689 | 13,987 | 15.3 K to 14 K (-8.84 %) |
| Jan 06 2021 | XLRN | ACCELERON PHARMA I ... | Backstrom Jay T. | EVP, Research and D ... | Payment of Exercise | F | 124.31 | 1,735 | 215,678 | 15,372 | 17.1 K to 15.4 K (-10.14 %) |
| Jan 06 2021 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 123.50 | 4 | 494 | 5,813 | 5.8 K to 5.8 K (-0.07 %) |
| Jan 06 2021 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 122.85 | 296 | 36,364 | 5,817 | 6.1 K to 5.8 K (-4.84 %) |
| Jan 06 2021 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 121.89 | 499 | 60,823 | 6,113 | 6.6 K to 6.1 K (-7.55 %) |
| Jan 06 2021 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 120.43 | 700 | 84,301 | 6,612 | 7.3 K to 6.6 K (-9.57 %) |
| Jan 06 2021 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 124.45 | 300 | 37,335 | 7,312 | 7.6 K to 7.3 K (-3.94 %) |
| Jan 06 2021 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 124.47 | 667 | 83,021 | 7,612 | 8.3 K to 7.6 K (-8.06 %) |
| Jan 06 2021 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 123.49 | 600 | 74,094 | 8,279 | 8.9 K to 8.3 K (-6.76 %) |
| Jan 06 2021 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 125.49 | 200 | 25,098 | 8,879 | 9.1 K to 8.9 K (-2.20 %) |
| Jan 06 2021 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 124.28 | 713 | 88,612 | 9,079 | 9.8 K to 9.1 K (-7.28 %) |
| Jan 06 2021 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 123.54 | 800 | 98,832 | 9,792 | 10.6 K to 9.8 K (-7.55 %) |
| Jan 06 2021 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Payment of Exercise | F | 124.31 | 624 | 77,569 | 10,592 | 11.2 K to 10.6 K (-5.56 %) |
| Jan 06 2021 | XLRN | ACCELERON PHARMA I ... | Dable Habib J | CEO and President | Sell | S | 122.55 | 94 | 11,520 | 81,788 | 81.9 K to 81.8 K (-0.11 %) |
| Jan 06 2021 | XLRN | ACCELERON PHARMA I ... | Dable Habib J | CEO and President | Sell | S | 122.46 | 764 | 93,559 | 81,882 | 82.6 K to 81.9 K (-0.92 %) |
| Jan 06 2021 | XLRN | ACCELERON PHARMA I ... | Dable Habib J | CEO and President | Sell | S | 121.55 | 900 | 109,395 | 82,646 | 83.5 K to 82.6 K (-1.08 %) |
| Jan 06 2021 | XLRN | ACCELERON PHARMA I ... | Dable Habib J | CEO and President | Sell | S | 120.52 | 2,500 | 301,300 | 83,546 | 86 K to 83.5 K (-2.91 %) |
| Jan 06 2021 | XLRN | ACCELERON PHARMA I ... | Dable Habib J | CEO and President | Payment of Exercise | F | 124.31 | 3,278 | 407,488 | 86,046 | 89.3 K to 86 K (-3.67 %) |
| Dec 15 2020 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 40.61 | 2,590 | 105,180 | 26,262 | |
| Dec 15 2020 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 30.17 | 24,986 | 753,828 | 5,163 | |
| Dec 15 2020 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 27.97 | 7,700 | 215,369 | 0 | |
| Dec 15 2020 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 41.20 | 7,252 | 298,782 | 0 | |
| Dec 15 2020 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 130.14 | 42,528 | 5,534,594 | 11,216 | 53.7 K to 11.2 K (-79.13 %) |
| Dec 15 2020 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 40.61 | 2,590 | 105,180 | 53,744 | 51.2 K to 53.7 K (+5.06 %) |
| Dec 15 2020 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 30.17 | 24,986 | 753,828 | 51,154 | 26.2 K to 51.2 K (+95.48 %) |
| Dec 15 2020 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 27.97 | 7,700 | 215,369 | 26,168 | 18.5 K to 26.2 K (+41.69 %) |
| Dec 15 2020 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 41.20 | 7,252 | 298,782 | 18,468 | 11.2 K to 18.5 K (+64.66 %) |
| Dec 11 2020 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 41.20 | 3,100 | 127,720 | 7,252 | |
| Dec 11 2020 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 40.61 | 100 | 4,061 | 28,852 | |
| Dec 11 2020 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 30.17 | 100 | 3,017 | 30,149 | |
| Dec 11 2020 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 27.97 | 200 | 5,594 | 7,700 | |
| Dec 11 2020 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 41.20 | 100 | 4,120 | 10,352 | |
| Dec 11 2020 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 40.61 | 1,873 | 76,063 | 28,952 | |
| Dec 11 2020 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 30.17 | 1,051 | 31,709 | 30,249 | |
| Dec 11 2020 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 27.97 | 400 | 11,188 | 7,900 | |
| Dec 11 2020 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 41.20 | 548 | 22,578 | 10,452 | |
| Dec 11 2020 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 125.00 | 3,100 | 387,500 | 11,216 | 14.3 K to 11.2 K (-21.65 %) |
| Dec 11 2020 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 41.20 | 3,100 | 127,720 | 14,316 | 11.2 K to 14.3 K (+27.64 %) |
| Dec 11 2020 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 125.12 | 500 | 62,560 | 11,216 | 11.7 K to 11.2 K (-4.27 %) |
| Dec 11 2020 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 40.61 | 100 | 4,061 | 11,716 | 11.6 K to 11.7 K (+0.86 %) |
| Dec 11 2020 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 30.17 | 100 | 3,017 | 11,616 | 11.5 K to 11.6 K (+0.87 %) |
| Dec 11 2020 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 27.97 | 200 | 5,594 | 11,516 | 11.3 K to 11.5 K (+1.77 %) |
| Dec 11 2020 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 41.20 | 100 | 4,120 | 11,316 | 11.2 K to 11.3 K (+0.89 %) |
| Dec 11 2020 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 125.03 | 3,872 | 484,116 | 11,216 | 15.1 K to 11.2 K (-25.66 %) |
| Dec 11 2020 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 40.61 | 1,873 | 76,063 | 15,088 | 13.2 K to 15.1 K (+14.17 %) |
| Dec 11 2020 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 30.17 | 1,051 | 31,709 | 13,215 | 12.2 K to 13.2 K (+8.64 %) |
| Dec 11 2020 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 27.97 | 400 | 11,188 | 12,164 | 11.8 K to 12.2 K (+3.40 %) |
| Dec 11 2020 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 41.20 | 548 | 22,578 | 11,764 | 11.2 K to 11.8 K (+4.89 %) |
| Oct 13 2020 | XLRN | ACCELERON PHARMA I ... | Kearney Terrence C | Director | Option Exercise | M | 30.17 | 7,500 | 226,275 | 0 | |
| Oct 13 2020 | XLRN | ACCELERON PHARMA I ... | Kearney Terrence C | Director | Option Exercise | M | 27.97 | 10,000 | 279,700 | 0 | |
| Oct 13 2020 | XLRN | ACCELERON PHARMA I ... | Kearney Terrence C | Director | Option Exercise | M | 28.37 | 20,000 | 567,400 | 0 | |
| Oct 13 2020 | XLRN | ACCELERON PHARMA I ... | Kearney Terrence C | Director | Sell | S | 120.57 | 913 | 110,080 | 5,127 | 6 K to 5.1 K (-15.12 %) |
| Oct 13 2020 | XLRN | ACCELERON PHARMA I ... | Kearney Terrence C | Director | Sell | S | 119.78 | 16,210 | 1,941,634 | 6,040 | 22.3 K to 6 K (-72.85 %) |
| Oct 13 2020 | XLRN | ACCELERON PHARMA I ... | Kearney Terrence C | Director | Sell | S | 119.11 | 18,177 | 2,165,062 | 22,250 | 40.4 K to 22.3 K (-44.96 %) |
| Oct 13 2020 | XLRN | ACCELERON PHARMA I ... | Kearney Terrence C | Director | Sell | S | 117.82 | 2,200 | 259,204 | 40,427 | 42.6 K to 40.4 K (-5.16 %) |
| Oct 13 2020 | XLRN | ACCELERON PHARMA I ... | Kearney Terrence C | Director | Buy | M | 30.17 | 7,500 | 226,275 | 42,627 | 35.1 K to 42.6 K (+21.35 %) |
| Oct 13 2020 | XLRN | ACCELERON PHARMA I ... | Kearney Terrence C | Director | Buy | M | 27.97 | 10,000 | 279,700 | 35,127 | 25.1 K to 35.1 K (+39.80 %) |
| Oct 13 2020 | XLRN | ACCELERON PHARMA I ... | Kearney Terrence C | Director | Buy | M | 28.37 | 20,000 | 567,400 | 25,127 | 5.1 K to 25.1 K (+390.09 %) |
| Sep 17 2020 | XLRN | ACCELERON PHARMA I ... | Hamill Laura | Director | Option Exercise | A | 101.88 | 9,339 | 951,457 | 9,339 | |
| Sep 15 2020 | XLRN | ACCELERON PHARMA I ... | MCCOURT Thomas A | Director | Option Exercise | M | 30.17 | 3,272 | 98,716 | 0 | |
| Sep 15 2020 | XLRN | ACCELERON PHARMA I ... | MCCOURT Thomas A | Director | Option Exercise | M | 32.98 | 20,000 | 659,600 | 0 | |
| Sep 15 2020 | XLRN | ACCELERON PHARMA I ... | MCCOURT Thomas A | Director | Sell | S | 91.38 | 200 | 18,276 | 4,422 | 4.6 K to 4.4 K (-4.33 %) |
| Sep 15 2020 | XLRN | ACCELERON PHARMA I ... | MCCOURT Thomas A | Director | Sell | S | 90.64 | 13,896 | 1,259,533 | 4,622 | 18.5 K to 4.6 K (-75.04 %) |
| Sep 15 2020 | XLRN | ACCELERON PHARMA I ... | MCCOURT Thomas A | Director | Sell | S | 89.98 | 9,176 | 825,656 | 18,518 | 27.7 K to 18.5 K (-33.13 %) |
| Sep 15 2020 | XLRN | ACCELERON PHARMA I ... | MCCOURT Thomas A | Director | Buy | M | 30.17 | 3,272 | 98,716 | 27,694 | 24.4 K to 27.7 K (+13.40 %) |
| Sep 15 2020 | XLRN | ACCELERON PHARMA I ... | MCCOURT Thomas A | Director | Buy | M | 32.98 | 20,000 | 659,600 | 24,422 | 4.4 K to 24.4 K (+452.28 %) |
| Sep 15 2020 | XLRN | ACCELERON PHARMA I ... | MCCOURT Thomas A | Director | Option Exercise | M | 30.17 | 3,272 | 98,716 | 0 | |
| Sep 15 2020 | XLRN | ACCELERON PHARMA I ... | MCCOURT Thomas A | Director | Option Exercise | M | 32.98 | 20,000 | 659,600 | 0 | |
| Sep 15 2020 | XLRN | ACCELERON PHARMA I ... | MCCOURT Thomas A | Director | Sell | S | 91.38 | 200 | 18,276 | 4,422 | 4.6 K to 4.4 K (-4.33 %) |
| Sep 15 2020 | XLRN | ACCELERON PHARMA I ... | MCCOURT Thomas A | Director | Sell | S | 90.64 | 13,896 | 1,259,533 | 4,622 | 18.5 K to 4.6 K (-75.04 %) |
| Sep 15 2020 | XLRN | ACCELERON PHARMA I ... | MCCOURT Thomas A | Director | Sell | S | 89.98 | 9,176 | 825,656 | 18,518 | 27.7 K to 18.5 K (-33.13 %) |
| Sep 15 2020 | XLRN | ACCELERON PHARMA I ... | MCCOURT Thomas A | Director | Buy | M | 30.17 | 3,272 | 98,716 | 27,694 | 24.4 K to 27.7 K (+13.40 %) |
| Sep 15 2020 | XLRN | ACCELERON PHARMA I ... | MCCOURT Thomas A | Director | Buy | M | 32.98 | 20,000 | 659,600 | 24,422 | 4.4 K to 24.4 K (+452.28 %) |
| Sep 09 2020 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | SVP, General Counse ... | Sell | S | 89.85 | 929 | 83,471 | 19,161 | 20.1 K to 19.2 K (-4.62 %) |
| Sep 09 2020 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | SVP, General Counse ... | Sell | S | 89.20 | 1,071 | 95,533 | 20,090 | 21.2 K to 20.1 K (-5.06 %) |
| Jul 13 2020 | XLRN | ACCELERON PHARMA I ... | CELGENE CORP /DE/ | 10% Owner | Option Exercise | X | 5.88 | 38,979 | 229,197 | 0 | |
| Jul 13 2020 | XLRN | ACCELERON PHARMA I ... | CELGENE CORP /DE/ | 10% Owner | Sell | S | 102.28 | 2,241 | 229,209 | 7,008,510 | 7 M to 7 M (-0.03 %) |
| Jul 13 2020 | XLRN | ACCELERON PHARMA I ... | CELGENE CORP /DE/ | 10% Owner | Buy | X | 5.88 | 38,979 | 229,197 | 7,010,751 | 7 M to 7 M (+0.56 %) |
| Jul 06 2020 | XLRN | ACCELERON PHARMA I ... | Dable Habib J | CEO and President | Option Exercise | M | 35.04 | 50,000 | 1,752,000 | 350,000 | |
| Jul 06 2020 | XLRN | ACCELERON PHARMA I ... | Dable Habib J | CEO and President | Sell | S | 99.42 | 1,100 | 109,362 | 89,324 | 90.4 K to 89.3 K (-1.22 %) |
| Jul 06 2020 | XLRN | ACCELERON PHARMA I ... | Dable Habib J | CEO and President | Sell | S | 98.57 | 4,400 | 433,708 | 90,424 | 94.8 K to 90.4 K (-4.64 %) |
| Jul 06 2020 | XLRN | ACCELERON PHARMA I ... | Dable Habib J | CEO and President | Sell | S | 97.43 | 9,534 | 928,898 | 94,824 | 104.4 K to 94.8 K (-9.14 %) |
| Jul 06 2020 | XLRN | ACCELERON PHARMA I ... | Dable Habib J | CEO and President | Sell | S | 96.49 | 15,219 | 1,468,481 | 104,358 | 119.6 K to 104.4 K (-12.73 %) |